Navigation Links
Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax

treatments began 24 hours after exposure to B. anthracis spores. Survival rates at 30 days post- exposure were as follows: 90 percent survival with CIP and 100 percent survival with ORI treatment at doses equal to or greater than 3 mg/kg intraperitoneally (multiple dose) or 50 mg/kg intravenously (single dose).

A follow-up experiment showed that ORI or CIP provided significant survival rates even when the start of treatment was delayed to either 36 or 48 hours post-exposure to spores (i.e., until symptoms had begun to appear). In this experiment, ORI was administered at 10 mg/kg once every 2 days while CIP was administered at 30 mg/kg twice daily. Treatments were provided intraperitoneally for 14 days and survivorship was measured at 30 days.

In addition, a single 50 mg/kg intravenous dose of ORI administered 24 hours prior to anthrax exposure provided a 100 percent survival rate at 30 days.

Researchers at USAMRIID and Targanta concluded that their results provide impetus for investigation of whether ORI could serve as an effective therapy for anthrax exposure, requiring fewer doses compared to CIP, or perhaps even as a potential prophylactic agent.

B. anthracis, a bacterium that forms spores and causes anthrax, has been recognized for more than 60 years as a potential biological warfare agent. Such was the case in 2001, when B. anthracis spores were distributed through the U.S. Postal Service, causing 22 cases of anthrax, including five deaths. If treated promptly B. anthracis usually responds effectively to several antibiotics including penicillin, doxycycline and fluoroquinolones (including ciprofloxacin). Though ciprofloxacin is the current standard of treatment for exposure, anthrax has the possibility of being engineered to be multi-drug resistant, which would complicate treatment. The World Health Organization estimates that 50 kg of B. anthracis spores effectively released in a population of 500,000 people would result in 95,000
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:7/28/2015)... , July 28, 2015  ULURU Inc. (OTCQB: ULUR) ... Stockholders and the appointment of Bradley J. Sacks ... Company,s Board of Directors has determined that the 2015 Annual ... 25, 2015 at 10:00 a.m., Central Daylight Time at the ... TX 75001. In accordance with the ...
(Date:7/28/2015)... 2015  Cepheid (Nasdaq: CPHD ) today ... clinical molecular diagnostic system designed to meet the ... just 9 inches tall, and weighing just 2.2 ... high quality PCR-based Xpert® cartridges as Cepheid,s existing ... molecular diagnostic tests to be performed in any ...
(Date:7/28/2015)... , July 20, 2015 ... addition of the "Global Post-traumatic Stress Disorder Therapeutics ... The global PTSD therapeutics market to grow at a ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
Breaking Medicine Technology:ULURU Inc. Announces The Schedule For The 2015 Annual Meeting Of Stockholders And The Appointment Of Bradley J. Sacks To The Board Of Directors 2ULURU Inc. Announces The Schedule For The 2015 Annual Meeting Of Stockholders And The Appointment Of Bradley J. Sacks To The Board Of Directors 3World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 2World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 3World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC 4Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - Growing Number of Accidents and Violence Worldwide Drives the Market 2
... 10, 2012 /PRNewswire-Asia/ -- QIAGEN (NASDAQ: QGEN ; ... its therascreen ® EGFR Mutation Detection Kit ... been shown to play an important role in certain cancers ... The approval is a milestone in QIAGEN,s Personalized ...
... 2012  Hanger Orthopedic Group, Inc. (NYSE: HGR ) ... operations for the quarter ended December 31, 2011, on Thursday, ... a press release announcing the results for the quarter ended ... Wednesday, February 8, 2012 after the close of the market. ...
Cached Medicine Technology:QIAGEN Receives Regulatory Approval in Japan for EGFR Companion Diagnostic to Guide Cancer Treatments 2QIAGEN Receives Regulatory Approval in Japan for EGFR Companion Diagnostic to Guide Cancer Treatments 3QIAGEN Receives Regulatory Approval in Japan for EGFR Companion Diagnostic to Guide Cancer Treatments 4Hanger Orthopedic Group, Inc. Announces Fourth Quarter 2011 Earnings Release Conference Call 2
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... According to ... able to stop the cycle of addiction in lab mice. The study involving isradipine ... for the new prospect of helping their clients overcome drug and alcohol addictions. The ...
(Date:7/28/2015)... ... July 28, 2015 , ... Bipolar disorder is often associated with mood swings ... times a year. The World Health Organization (WHO) has reported that bipolar disorder affects ... Health reveals that the United States has the highest lifetime rate of bipolar disorder ...
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard ... authorized the Company, from time to time and depending on market conditions, to ... to $25 million. Repurchases will be made in open market or privately negotiated ...
(Date:7/28/2015)... ... 28, 2015 , ... Fertility specialist Dr. Lisa Hasty of Atlanta ... Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has been recognized ... peers in the metro area as one of the most respected doctors in Reproductive ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom are missed ... the identification of individuals with active yet undetected sub-clinical disease, who are at ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... (HealthDay News) -- In men who,ve had their prostate surgically ... a rise in blood levels of prostate specific antigen (PSA) ... So finds a new study slated to be presented Monday ... in Washington, D.C. The study included 321 smokers ...
... --,More than half of those who develop Alzheimer,s disease before ... signs of the disease are symptoms other than memory problems, ... of 40 people from Barcelona who were found to have ... the age at which the symptoms began, as well as ...
... of workshops held by the Institute of Medicine explored ... to harness the full potential of new digital technologies ... efficiency and apply knowledge to real-time care decisions. , ... for Continuous Improvement in Health and Health Care recaps ...
... strong commitment to medical and health research and recognize ... and the nation,s economy, according to a new statewide ... Ohio Medical University (NEOMED). A strong majority ... important42% say very importantto the state,s economy. Eight in ...
... is the fourth-most-common cancer in men and one of ... death. After initial diagnosis and surgery, patients must return ... time-consuming and uncomfortable bladder scan. Tumors recur in more ... Washington are proposing a more automated approach that could ...
... Researchers at Sandia National Laboratories have developed a ... about exactly how and why a cell,s defenses ... successfully fending off others like E.coli. The approach ... which could open doors to new diagnostic, prevention ...
Cached Medicine News:Health News:Research Shows Early Onset Alzheimer's Disease Sometimes Missed 2Health News:Ohio residents: Medical and health research important to state's economy, jobs and incomes 2Health News:Ohio residents: Medical and health research important to state's economy, jobs and incomes 3Health News:Digital imaging software to create a 'Google Earth' view of the bladder 2Health News:Digital imaging software to create a 'Google Earth' view of the bladder 3Health News:Sandia Labs unlocks secrets of plague with stunning new imaging techniques 2Health News:Sandia Labs unlocks secrets of plague with stunning new imaging techniques 3
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 15 mm blades allow intraocular manipulation without metal to metal contact. 16 mm lifting wings. Dull finish....
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Medicine Products: